These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

240 related articles for article (PubMed ID: 35695059)

  • 1. The onset of PI3K-related vascular malformations occurs during angiogenesis and is prevented by the AKT inhibitor miransertib.
    Kobialka P; Sabata H; Vilalta O; Gouveia L; Angulo-Urarte A; Muixí L; Zanoncello J; Muñoz-Aznar O; Olaciregui NG; Fanlo L; Esteve-Codina A; Lavarino C; Javierre BM; Celis V; Rovira C; López-Fernández S; Baselga E; Mora J; Castillo SD; Graupera M
    EMBO Mol Med; 2022 Jul; 14(7):e15619. PubMed ID: 35695059
    [TBL] [Abstract][Full Text] [Related]  

  • 2. PI3K/mTOR inhibition promotes the regression of experimental vascular malformations driven by PIK3CA-activating mutations.
    di Blasio L; Puliafito A; Gagliardi PA; Comunanza V; Somale D; Chiaverina G; Bussolino F; Primo L
    Cell Death Dis; 2018 Jan; 9(2):45. PubMed ID: 29352118
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinical experience with the AKT1 inhibitor miransertib in two children with PIK3CA-related overgrowth syndrome.
    Forde K; Resta N; Ranieri C; Rea D; Kubassova O; Hinton M; Andrews KA; Semple R; Irvine AD; Dvorakova V
    Orphanet J Rare Dis; 2021 Feb; 16(1):109. PubMed ID: 33639990
    [TBL] [Abstract][Full Text] [Related]  

  • 4. In vitro efficacy of ARQ 092, an allosteric AKT inhibitor, on primary fibroblast cells derived from patients with PIK3CA-related overgrowth spectrum (PROS).
    Ranieri C; Di Tommaso S; Loconte DC; Grossi V; Sanese P; Bagnulo R; Susca FC; Forte G; Peserico A; De Luisi A; Bartuli A; Selicorni A; Melis D; Lerone M; Praticò AD; Abbadessa G; Yu Y; Schwartz B; Ruggieri M; Simone C; Resta N
    Neurogenetics; 2018 May; 19(2):77-91. PubMed ID: 29549527
    [TBL] [Abstract][Full Text] [Related]  

  • 5. A review of mechanisms of disease across PIK3CA-related disorders with vascular manifestations.
    Canaud G; Hammill AM; Adams D; Vikkula M; Keppler-Noreuil KM
    Orphanet J Rare Dis; 2021 Jul; 16(1):306. PubMed ID: 34238334
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Shear stress and pathophysiological PI3K involvement in vascular malformations.
    Abdelilah-Seyfried S; Ola R
    J Clin Invest; 2024 May; 134(10):. PubMed ID: 38747293
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comprehensive phenotypic and genomic characterization of venous malformations.
    Hirose K; Hori Y; Ozeki M; Motooka D; Hata K; Tahara S; Matsui T; Kohara M; Maruyama K; Imanaka-Yoshida K; Toyosawa S; Morii E
    Hum Pathol; 2024 Mar; 145():48-55. PubMed ID: 38367816
    [TBL] [Abstract][Full Text] [Related]  

  • 8. PIK3CA mutations in vascular malformations.
    Castillo SD; Baselga E; Graupera M
    Curr Opin Hematol; 2019 May; 26(3):170-178. PubMed ID: 30855339
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comprehensive targeted next-generation sequencing in patients with slow-flow vascular malformations.
    Nozawa A; Fujino A; Yuzuriha S; Suenobu S; Kato A; Shimizu F; Aramaki-Hattori N; Kuniyeda K; Sakaguchi K; Ohnishi H; Aoki Y; Ozeki M
    J Hum Genet; 2022 Dec; 67(12):721-728. PubMed ID: 36171295
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Somatic activating mutations in Pik3ca cause sporadic venous malformations in mice and humans.
    Castillo SD; Tzouanacou E; Zaw-Thin M; Berenjeno IM; Parker VE; Chivite I; Milà-Guasch M; Pearce W; Solomon I; Angulo-Urarte A; Figueiredo AM; Dewhurst RE; Knox RG; Clark GR; Scudamore CL; Badar A; Kalber TL; Foster J; Stuckey DJ; David AL; Phillips WA; Lythgoe MF; Wilson V; Semple RK; Sebire NJ; Kinsler VA; Graupera M; Vanhaesebroeck B
    Sci Transl Med; 2016 Mar; 8(332):332ra43. PubMed ID: 27030595
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Neutralization of HSF1 in cells from PIK3CA-related overgrowth spectrum patients blocks abnormal proliferation.
    Da Costa R; De Almeida S; Chevarin M; Hadj-Rabia S; Leclerc-Mercier S; Thauvin-Robinet C; Garrido C; Faivre L; Vabres P; Duplomb L; Jego G
    Biochem Biophys Res Commun; 2020 Sep; 530(3):520-526. PubMed ID: 32620236
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Constitutively active PIK3CA mutations are expressed by lymphatic and vascular endothelial cells in capillary lymphatic venous malformation.
    Le Cras TD; Goines J; Lakes N; Pastura P; Hammill AM; Adams DM; Boscolo E
    Angiogenesis; 2020 Aug; 23(3):425-442. PubMed ID: 32350708
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Somatic PIK3CA mutations as a driver of sporadic venous malformations.
    Castel P; Carmona FJ; Grego-Bessa J; Berger MF; Viale A; Anderson KV; Bague S; Scaltriti M; Antonescu CR; Baselga E; Baselga J
    Sci Transl Med; 2016 Mar; 8(332):332ra42. PubMed ID: 27030594
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Syndromic vascular malformations related to the PIK3CA and RAS pathways: A clinical and imaging review.
    Tsujioka Y; Nozaki T; Niimi Y; Starkey J; Hasegawa D; Kondo M; Enokizono M; Makidono A; Kono T; Jinzaki M
    Clin Imaging; 2022 Sep; 89():162-173. PubMed ID: 35849880
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A xenograft model for venous malformation.
    Goines J; Li X; Cai Y; Mobberley-Schuman P; Metcalf M; Fishman SJ; Adams DM; Hammill AM; Boscolo E
    Angiogenesis; 2018 Nov; 21(4):725-735. PubMed ID: 29786783
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New and Emerging Targeted Therapies for Vascular Malformations.
    Van Damme A; Seront E; Dekeuleneer V; Boon LM; Vikkula M
    Am J Clin Dermatol; 2020 Oct; 21(5):657-668. PubMed ID: 32557381
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Endothelial hyperactivation of mutant MAP3K3 induces cerebral cavernous malformation enhanced by PIK3CA GOF mutation.
    Huo R; Yang Y; Sun Y; Zhou Q; Zhao S; Mo Z; Xu H; Wang J; Weng J; Jiao Y; Zhang J; He Q; Wang S; Zhao J; Wang J; Cao Y
    Angiogenesis; 2023 May; 26(2):295-312. PubMed ID: 36719480
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Somatic frameshift mutation in PIK3CA causes CLOVES syndrome by provoking PI3K/AKT/mTOR pathway.
    Yan W; Zhang B; Wang H; Mo R; Jiang X; Qin W; Ma L; Lin Z
    Hereditas; 2021 Jun; 158(1):18. PubMed ID: 34074347
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of rapamycin, NVP-BEZ235, aspirin, and metformin on PI3K/AKT/mTOR signaling pathway of PIK3CA-related overgrowth spectrum (PROS).
    Suzuki Y; Enokido Y; Yamada K; Inaba M; Kuwata K; Hanada N; Morishita T; Mizuno S; Wakamatsu N
    Oncotarget; 2017 Jul; 8(28):45470-45483. PubMed ID: 28525374
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Updates on Diagnosis and Treatment of PIK3CA-Related Overgrowth Spectrum.
    Chen H; Gao W; Liu H; Sun B; Hua C; Lin X
    Ann Plast Surg; 2023 May; 90(5S Suppl 2):S209-S215. PubMed ID: 36729078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.